AlphAIAlphAI — Financial news for AI agents
SEC EDGAR$BOLT

Coastlands Capital LP purchased $319K of BOLT (indirect holdings)

Coastlands Capital LP purchased 50,000 indirectly-held shares of Bolt Biotherapeutics, Inc. (BOLT) at $6.38 ($0.32M total) on 2026-11-09.

Original reporting
SEC EDGAR · Coastlands Capital LP
Published Nov 10, 2026, 7:57 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 10, 2026, 7:59 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$BOLT
Bullish
medium confidence
Mentioned
$BOLT
Relevance
5/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$BOLTBullishLow
01

Why it matters

Insider buying can be a bullish indicator, but the modest size limits market reaction.

02

Market read

Provides a fresh insider purchase signal for BOLT, offering a low‑impact trading cue.

03

What to watch

Potential upcoming clinical milestones could be driving the insider's decision.

Relevance 5/10Novelty 5/10Timing: today

Background

SEC Form 4 filing discloses insider transactions for public companies.

Company-level read

Ticker impact

$BOLTBullishMedium confidence
Context

Coastlands Capital LP bought 50,000 shares of Bolt Biotherapeutics at $6.38, a $319K insider purchase increasing its stake to 462,416 shares.

Expected impact

likely slight upward pressure as the market prices in the insider buying.

Evidence & confidence

Small but notable purchase by a significant shareholder; market typically reacts modestly to insider buys of this size.

Market effects

Sector

Minimal impact on biotech sector; similar insider purchases are common.

Regional

No regional effect beyond the company's share price.

Global

Limited to investors tracking Bolt Biotherapeutics.

Counterpoint

What could challenge this read

The purchase may be a routine portfolio rebalancing rather than a strong confidence signal.

Key entities

  • company
    Bolt Biotherapeutics, Inc.

    Biotech firm developing therapies, ticker BOLT.

  • investor
    Coastlands Capital LP

    Investment entity acquiring a 10% stake in Bolt Biotherapeutics.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

BOLT insider trading history →

Related articles

$BOLTHighAI 8/10

Bolt Biotherapeutics Reports Third Quarter 2026 Financial Results and Provides Business Update

Bolt Biotherapeutics, Inc. (BOLT) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Bolt Biotherapeutics Reports Third Quarter 2026 Financial Results and Provides Business Update • Completed acquisition of Prana Therapies and $120 million concurrent private placement financing, establishing PRA-216 and the INSPIRE-built pipeline as Bolt’s primary de

SEC EDGAR 8-K
$BOLTHigh

Bolt Biotherapeutics, Inc. (BOLT): Completion of Acquisition or Disposition of Assets

Bolt Biotherapeutics, Inc. (BOLT) filed an SEC Form 8-K — Completion of Acquisition or Disposition of Assets. Exhibit 99.1 Bolt Biotherapeutics Announces Acquisition of Prana Therapies and $120 Million Concurrent Private Placement to Advance PRA-216 in Multiple High-Value Inflammatory Indications • Transactions position the company to advance Prana’s pipeline of next-generation, half-lif

SEC EDGAR 8-K